GRAZAX standardised allergen extract of grass pollen from Timothy grass (Phleum pratense) 75,000 SQ-T sublingual tablets blister foil Australia - English - Department of Health (Therapeutic Goods Administration)

grazax standardised allergen extract of grass pollen from timothy grass (phleum pratense) 75,000 sq-t sublingual tablets blister foil

seqirus pty ltd - phleum pratense, quantity: 75000 sq-t - tablet - excipient ingredients: gelatin; mannitol; sodium hydroxide; purified water - grazax is indicated for disease modifying treatment of grass pollen (phleum pratense or allergens cross reacting with p. pratense) induced allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years.

5 GRASS MIX- phleum pratense pollen, dactylis glomerata pollen, poa pratensis pollen, agrostis gigantea pollen, anthoxanthum odo United States - English - NLM (National Library of Medicine)

5 grass mix- phleum pratense pollen, dactylis glomerata pollen, poa pratensis pollen, agrostis gigantea pollen, anthoxanthum odo

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 1000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants, in situations where the offending allergen cannot be avoided. prior to the initiation of therapy, clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can be easily avoided. a patient should not be immunized against a substance which the patient has not demonstrated symptoms and/or tissue-fixed ige antibodies as demonstrated by skin testing. immunotherapy should not be attempted in patients with active asthma, severe respiratory obstruction, or cardiovascular disease. there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases. hyposensitization should be given cautiously to patients with this predisposition. the physician must w

ORALAIR Continuation Treatment Sublingual (Allergen pollen Extract of 5 grasses) Tablets 300IR blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

oralair continuation treatment sublingual (allergen pollen extract of 5 grasses) tablets 300ir blister pack

stallergenes australia pty ltd - poa pratensis, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; phleum pratense, quantity: 20 %; dactylis glomerata, quantity: 20 %; lolium perenne, quantity: 20 % - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

ORALAIR Initiation Treatment, Sublingual (Allergen pollen Extract of 5 grasses) Tablets 100IR & 300IR Blister Pack Australia - English - Department of Health (Therapeutic Goods Administration)

oralair initiation treatment, sublingual (allergen pollen extract of 5 grasses) tablets 100ir & 300ir blister pack

stallergenes australia pty ltd - lolium perenne, quantity: 20 %; phleum pratense, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; dactylis glomerata, quantity: 20 %; poa pratensis, quantity: 20 % - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

ALLERGEN PACK TIMOTHY GRASS solution United States - English - NLM (National Library of Medicine)

allergen pack timothy grass solution

alvix laboratories, llc - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg) - phleum pratense pollen 10000 [bau] in 1 ml

Timothy Grass (Phleum pratense) pollen 100DBU/ml solution for skin prick test United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

timothy grass (phleum pratense) pollen 100dbu/ml solution for skin prick test

phleum pratense) pollen 100dbu/ml solution for skin prick test (lofarma - timothy grass (phleum pratense) pollen allergen extract - solution for skin-prick test

Timothy Grass (Phleum pratense) pollen 50HEP/ml solution for skin prick test United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

timothy grass (phleum pratense) pollen 50hep/ml solution for skin prick test

phleum pratense) pollen 50hep/ml solution for skin prick test (inmunotek - timothy grass (phleum pratense) pollen allergen extract - solution for skin-prick test

ORALAIR- anthoxanthum odoratum pollen, dactylis glomerata pollen, lolium perenne pollen, phelum pratense pollen, and poa pratens United States - English - NLM (National Library of Medicine)

oralair- anthoxanthum odoratum pollen, dactylis glomerata pollen, lolium perenne pollen, phelum pratense pollen, and poa pratens

stallergenes - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense top - unii:s7pw24bx20, phleum pratense pollen - unii:65m88rw2eg), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), lolium perenne pollen (unii: 4t81lb52r0) (lolium perenne pollen - unii:4t81lb52r0) - anthoxanthum odoratum pollen 100 [ir] - oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific ige antibodies for any of the five grass species contained in this product. oralair is approved for use in persons 5 through 65 years of age. oralair is not indicated for the immediate relief of allergy symptoms. oralair is contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic allergic reaction - history of any severe local reaction to sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients (mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate and lactose monohydrate) contained in this product [ see description (11) ] risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.

MIX OF 5 STANDARDIZED GRASS POLLEN- agrostis gigantea pollen, anthoxanthum odoratum pollen, dactylis glomerata pollen, phleum pr United States - English - NLM (National Library of Medicine)

mix of 5 standardized grass pollen- agrostis gigantea pollen, anthoxanthum odoratum pollen, dactylis glomerata pollen, phleum pr

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

MIX OF 5 STANDARD GRASS POLLEN- agrostis gigantea pollen, anthoxanthum odoratum pollen, dactylis glomerata pollen, phleum praten United States - English - NLM (National Library of Medicine)

mix of 5 standard grass pollen- agrostis gigantea pollen, anthoxanthum odoratum pollen, dactylis glomerata pollen, phleum praten

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe